Acquisition Target StrataDx was recently acquired by Fulgent Genetics, indicating strategic consolidation in the pathology diagnostics space. This suggests potential sales opportunities around integration services, data interoperability, and cross-sell of advanced molecular diagnostics and prognostic testing to the combined customer base.

Data Security A disclosed data breach involving sensitive personal information raises urgency for enhanced cybersecurity, compliance solutions, and incident response services. Propose offerings around secure data handling, breach remediation support, and ongoing risk assessment tailored to pathology labs.

Diagnostic Expansion StrataDx offers comprehensive molecular diagnostic and prognostic techniques alongside surgical pathology and cytology. There is opportunity to upsell additional molecular panels, liquid biopsy capabilities, and expanded DermSTAT-like tests to deepen the lab’s test menu and improve diagnostic confidence.

DermSTAT Success Historical DermSTAT launch signals a willingness to innovate in dermatopathology. Market this as a platform for further dermatology-focused assays, AI-assisted pathology tools, and collaborations with dermatology practices and hospitals seeking specialized skin infection diagnostics.

Growth Outlook With 51-200 employees and an annual revenue range of 10–25 million, StrataDx sits between mid-market labs and larger national players. Position solutions that scale with growth, including workflow automation, LIS integrations, and managed services designed for expanding national coverage.